Carlos Valladares

Dr. Carlos Valladares


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2025 in Lung
Verified
Journal Article
Open access
PDF file
CVCarlos Valladares
Carlos Valladares
BGBryan Gregory
Bryan Gregory
SSSheilabi Seeburun
Sheilabi Seeburun
AMAhmed Dawood Al Mahrizi
Ahmed Dawood Al Mahrizi
SSShreya Shambhavi
Shreya Shambhavi
WKWajahat Khan
Wajahat Khan
Purpose: Ventilator-associated pneumonia (VAP) is a common ICU complication linked to high morbidity and mortality. Inhaled antibiotics may offer targeted prophylaxis, but their effectiveness has shown mixed results. This study aims to further evaluate whether inhaled antibiotics reduce VAP incidence and ICU mortality through a systematic review and meta-analysis of the most updated available evidence. Methods: A systematic review was conducted following PRISMA 2020 guidelines. Multiple databases were searched for studies published up to November 14, 2024. Ten studies including 2876 patients (1485 intervention; 1391 control) met inclusion criteria. A random-effects meta-analysis was performed to estimate pooled risk ratios (RR) for VAP incidence and ICU mortality. Risk of bias was assessed using ROBINS-I and certainty of evidence via GRADE. Results: Inhaled antibiotics significantly reduced the incidence of VAP compared to controls (RR = 0.67; 95% CI: 0.58–0.77; p < 0.001), but showed no significant effect on ICU mortality (RR = 0.92; 95% CI: 0.79–1.06; p = 0.25). Moderate heterogeneity was observed in VAP outcomes ( I 2 = 46.8%), while mortality analysis showed no heterogeneity. Funnel plot analysis suggested minimal publication bias, and GRADE rated the evidence as moderate in certainty. Conclusion: Inhaled antibiotics significantly reduce VAP incidence but show no clear mortality benefit. While promising for prevention, their survival impact remains uncertain. Clinical use should consider patient context and microbial patterns for targeted approach. Future research should identify high-risk subgroups, assess long-term outcomes, and evaluate antibiotic resistance.

1 April 2025 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
CVCarlos Valladares
Carlos Valladares
ANAalia Narvel
Aalia Narvel
BKBianna Koutsenko
Bianna Koutsenko
ASAlexa Simonetti
Alexa Simonetti
FMFatima Mossolem
Fatima Mossolem
AKAdam Kaplan
Adam Kaplan
Background: Acute interstitial pneumonia (AIP), also known as Hamman-Rich syndrome, is a rapidly progressive interstitial lung disease. In addition to being challenging to diagnose, AIP is also difficult to treat. The mortality rate of AIP is greater than 70% due to the disease’s rapid progression. Furthermore, survivors are likely to develop chronic interstitial lung disease as a sequela. Treatment primarily focuses on supportive care, which consists of oxygenation through mechanical ventilation, administration of broad-spectrum antibiotics, and the use of corticosteroids. Although the use of steroids as empiric treatment is controversial and results on its mortality benefit are variable, some studies have shown high-dose pulse steroid therapy to be associated with better health outcomes. This review aimed to evaluate cases of AIP to better understand the role of corticosteroids in the management plan of these cases. Methods: A systematic review was conducted using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines. Outcomes of interest included patient age, sex, autoimmune condition, corticosteroid use, survival or expiration of patients, and time from hospitalization to expiration. Results: Initial querying of the five databases yielded 376 articles. Following a thorough review, only 30 articles remained, comprising 42 patient cases. Of these cases, 62% of the patients survived, 36% expired, and 2% were unknown. The average stay from hospitalization to death was 20.2 days, and corticosteroid pulse doses were used as a first- or second-line treatment in 31% of patients. Conclusion: The limitations of the evidence used in this study highlight the need for a greater output of higher-level evidence in the form of controlled trials and retrospective studies to help further elucidate the proper role and dosage of corticosteroids in the management plan of AIP with the ultimate goal of enhancing clinical decision-making and patient care. The findings of this systematic review, primarily based on observational data from case reports, highlight the critical need for treatment guidelines for this condition. The compilations of these cases also illustrated the diverse strategies employed by clinicians globally to save patients afflicted by this condition. While specific recommendations cannot be made based solely on these results, we anticipate that this comprehensive overview of varied clinical approaches from around the world will serve as a valuable resource for healthcare providers navigating the complexities of managing this condition.

1 January 2025 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
SSSheilabi Seeburun
Sheilabi Seeburun
CVCarlos Valladares
Carlos Valladares
JIJose Iglesias
Jose Iglesias
Pulmonary embolism (PE) and acute ischemic stroke (AIS) are serious conditions with high morbidity and mortality. In the USA, PE causes around 100,000 deaths annually, with higher incidence in males. AIS following PE occurs in 1-10% of cases and is a leading cause of death within 2 - 4 weeks post-stroke. Managing concurrent PE and AIS is complex due to the need for anticoagulation, which is contraindicated after thrombolysis for AIS. This review evaluates the impact of various PE treatments - anticoagulation, thrombolysis, and embolectomy - on mortality in patients with both conditions. Following PRISMA 2020 guidelines, a systematic review was conducted across six databases from January 2010 to December 2023. The primary outcome measured was mortality, comparing treated vs. untreated patients for PE. Secondary outcomes included marked symptom improvement, slight improvement or deterioration of symptoms, and the complications. Data were analyzed descriptively, summarizing patient demographics, clinical characteristics, and treatment outcomes. Treatment modalities, such as anticoagulation, thrombolysis, catheter-directed thrombectomy, surgical thrombectomy, and conservative management, were evaluated based on their impact on symptom improvement, survival, and mortality. Initial querying of six databases yielded 1,679 articles, with only 21 remaining after a thorough review. Thrombolysis led to 100% symptom improvement and survival, with 0% mortality. Anticoagulation resulted in symptom improvement and survival in 62.5% of cases, with a 12.5% mortality rate. Catheter-directed and surgical thrombectomy had symptom improvement and survival in 66.7% and 75% of cases, respectively, with no mortality. Conservative management, defined here as management without anticoagulation or thrombolytic therapy, was associated with symptom worsening or no improvement and 50% mortality. This systematic review, based on observational data from case reports, highlights the diverse strategies used by physicians. Proactive and aggressive treatments, especially thrombolysis, show better outcomes and lower mortality rates. However, specific recommendations cannot be made from these results alone, emphasizing the need for well-designed prospective, randomized controlled trials to design structured guidelines for healthcare providers.

24 October 2025 in Cureus
Verified
Journal Article
Open access
PDF file
CVCarlos Valladares
Carlos Valladares
CNCarlos Nuñez
Carlos Nuñez
EVErick Villacis
Erick Villacis
DADanny Allauca
Danny Allauca
SSSofia Simaluisa
Sofia Simaluisa
CVCarlos E. Núñez Vásquez
Carlos E. Núñez Vásquez
Saddle pulmonary embolism (SPE) is a rare but life-threatening presentation of venous thromboembolism (VTE). Recreational nitrous oxide (N₂O) use has become increasingly common and can cause a functional vitamin B12 deficiency that leads to elevated homocysteine levels and a prothrombotic state. We describe a 31-year-old man with ongoing N₂O abuse who presented with dyspnea and calf pain and was found to have a saddle pulmonary embolus and right leg deep vein thrombosis. Laboratory studies showed low vitamin B12 and high homocysteine levels. He was treated with anticoagulation and discharged in stable condition. This case highlights the need to consider N₂O exposure in patients with unexplained thrombosis, particularly in younger adults.

1 January 2025 in Critical Care Research and Practice
Verified
Journal Article
Open access
CVCarlos Valladares
Carlos Valladares
FBFranklyn Vega Batista
Franklyn Vega Batista
MFMarc Faltas
Marc Faltas
MMMareya Menteyas
Mareya Menteyas
KCKatherine Chiapaikeo-Poco
Katherine Chiapaikeo-Poco
Background: Prolonged use of intravenous (IV) vasopressors in critically ill patients is associated with significant complications. Droxidopa, a norepinephrine precursor approved for neurogenic orthostatic hypotension, has gained interest as an off‐label agent for facilitating vasopressor weaning in ICU settings. This systematic review aimed to evaluate the efficacy and safety of droxidopa for vasopressor weaning in ICU patients. Methods: A systematic review was conducted following PRISMA guidelines. Databases searched included PubMed, Embase, Cochrane, and Web of Science through April 2025. Eligible studies reporting primary clinical data on droxidopa use in ICU patients were included. Outcomes included time to IV vasopressor discontinuation, duration of droxidopa use, ICU length of stay (LOS), and ICU mortality, and results were narratively synthesized. The risk of bias was assessed using the ROBINS‐I and the JBI checklists. Results: Seven studies involving 161 ICU patients were included. Five studies reported time to vasopressor discontinuation, ranging from 29 to 120 h. The duration of droxidopa use ranged from 87 to 192 h. Two studies reported ICU LOS, ranging from 18 to 44 days. ICU mortality was inconsistently reported. These findings are primarily drawn from small, retrospective studies and should be interpreted cautiously. Discussion: Findings suggest that droxidopa may effectively facilitate vasopressor weaning in critically ill patients. However, variations in dosing, patient selection, and outcome reporting limit generalizability. Evidence is drawn primarily from small, retrospective studies, some available only as abstracts. Conclusion: Available evidence on droxidopa for vasopressor weaning in ICU patients remains limited and heterogeneous, with very low certainty. Further research is warranted. No funding was received for this review, and the review was not prospectively registered.

1 January 2025 in Case Reports in Cardiology
Verified
Journal Article
Open access
CVCarlos Valladares
Carlos Valladares
AKAdam Kaplan
Adam Kaplan
Background: The presence of cardiac manifestations, including bradycardia, has been described as a manifestation of coronavirus disease 2019 (COVID‐19). Our case report describes a case of sinus bradycardia secondary to possible sinus node dysfunction in an otherwise asymptomatic patient with COVID‐19. Case Presentation: We report the case of an unvaccinated 33‐year‐old female hospitalized due to bradycardia after 4 days of testing positive for COVID‐19. She presented with a 1‐day history of transitory lightheadedness and dizziness with no other associated symptoms. Sinus bradycardia was recorded on admission, heart rate 52/min that later dropped to 35/min on the second day of admission. Secondary causes of bradycardia were excluded based on the absence of relevant evidence from laboratory work‐up and echocardiographic examination. Decision‐Making: We recommend baseline ECG monitoring in hospitalized COVID‐19 patients, regardless of disease severity, to assess for potential cardiac manifestations. Conclusion: Cardiac rhythm monitoring is an essential component of staying vigilant against potential complications. It raises the question of how physicians should respond to a patient with marked bradycardia and when should they intervene?